SA
SRPT icon

Sovran Advisors’s Sarepta Therapeutics SRPT Stock Holding History

Sovran Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-61,643
Closed -$1.17M – 549
2025
Q2 		$1.17M Buy
61,643
+4,134
+7% +$176K 0.12% 182
2025
Q1 		$3.09M Buy
57,509
+30,494
+113% +$3.21M 0.4% 62
2024
Q4 		$3.21M Buy
+27,015
New +$3.31M 0.46% 55

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Sovran Advisors's SRPT Position: Q3 2025 in Review

Sovran Advisors sold out of Sarepta Therapeutics (SRPT) in Q3 2025, closing a stake of 61,643 shares — an estimated $1.17M sold.

Sovran Advisors first reported a position in SRPT in Q4 2024 and held it in 3 quarters. The position peaked at $3.21M in Q4 2024. 320 funds tracked by Wall St. Rank hold SRPT as of Q3 2025.

  • Sovran Advisors reported no remaining Sarepta Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Sovran Advisors sold 61,643 Sarepta Therapeutics shares in Q3 2025, an estimated $1.17M.
  • Sovran Advisors first reported a position in Sarepta Therapeutics in Q4 2024 and held it in 3 quarters.
  • Sovran Advisors's Sarepta Therapeutics position peaked at $3.21M in Q4 2024.
  • 320 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2025.

Based on Sovran Advisors's 13F filing for Q3 2025, filed 31 Oct 2025.